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Background. Spinal anaesthesia (SA) has high success rates. However, inadequate block after
SA has been reported even in the absence of technical problems. Various mechanisms for
failed SA (FSA) have been proposed, but reports of cerebrospinal fluid (CSF) concentrations of
local anaesthetics (LA) after FSA are scarce. We report lumbar CSF concentrations of bupiva-
caine in 20 patients in whom adequate block after subarachnoid injection failed to develop.
Methods. All patients with inadequate block after subarachnoid injection of plain bupivacaine
0.5% and in whom a second subarachnoid injection of LA was to be performed as a rescue
technique were eligible for entry into this study. A CSF sample was withdrawn immediately
before injection of the second dose of LA. Patients in whom failure was obviously due to tech-
nical problems or inadequate dosage were excluded. Bupivacaine concentrations were assessed
with high-performance liquid chromatography.
Results. During the study period of 15 months, 2600 spinal anaesthetics were performed.
The failure rate was 2.7% (71 patients). In 20 patients (0.77%), CSF concentrations of bupiva-
caine were determined, which ranged from 3.36 to 1020 mg ml21.
Conclusions. Inadequate CSF concentration of LA is a common reason for FSA. However, in
12 of our 20 patients, concentrations were above 73 mg ml21, a concentration that should
lead to an adequate block. In these patients, maldistribution of bupivacaine could be respon-
sible for FSA. In view of the absence of sufficient block, despite adequate lumbar CSF concen-
trations of bupivacaine, concerns about neurotoxicity with repeat injections may be warranted.
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Spinal anaesthesia (SA) is a frequently used anaesthetic
technique, and success rates and patient satisfaction are
generally high.1 However, there are numerous reports of
failed SA (FSA), and published failure rates in large series
of SA range from 0.46%2 to 17%.3 The reasons most com-
monly provided to explain failure are technical problems,3
errors of judgement with respect to pharmacological
factors, such as inadequate dose of local anaesthetic (LA),
and inadequate positioning of the patient.4 Proposed mech-
anisms for inadequate block despite correct dosing and
injection technique are maldistribution,5 variability in the
anatomy of the lumbar subarachnoid space,6 inadvertent
subdural7 or epidural injection,8 and resistance to the
effects of LA.9
Confronted with FSA, the anaesthesiologist can either
administer general anaesthesia or repeat the subarachnoid
injection with an identical or smaller dose of LA.
However, choosing an adequate dose of LA for a second
subarachnoid injection is difficult because the amount of
LA already present in the subarachnoid space is unknown.
A second dose may be too small, again resulting in an
inadequately low sensory level of anaesthesia or too large,
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leading to an inappropriately high level of anaesthesia. In
addition, reports of neurotoxic effects of LA10 and a corre-
lation between the dose of LA and the risk for
neurotoxicity11 call for cautious dosing when repeated sub-
arachnoid injections of LA are performed. In fact, neuro-
logical deficits associated with repeated subarachnoid
injection of LA after FSA have been reported,12 and the
safety of this practice has been questioned.13
We measured lumbar bupivacaine cerebrospinal fluid
(CSF) concentrations in patients with FSA to test the
hypothesis that the primary reason for FSA is an
inadequate concentration of LA in the CSF.
Methods
The study protocol was approved by the Regional Ethics
Committee of the University Hospital Basel, Basel,
Switzerland. The study lasted 15 months. For the purpose of
this study, we defined FSA as inadequate sensory block for
the planned procedure 15 min after subarachnoid injection
of an adequate standardized dose of LA. All patients who
fulfilled the definition of FSA and in whom SA had been
performed with plain bupivacaine 0.5% (Carbostesinw,
Astra Pharmaceutica AG, Dietikon, Switzerland) were eli-
gible for entry into the study. However, of these patients,
only those in whom the responsible anaesthesiologist
decided to use a second subarachnoid injection of LA as a
rescue technique were included, that is, no additional subar-
achnoid punctures were performed for study purposes only.
Exclusion criteria were patient refusal, pregnancy, obvious
technical difficulties during injection of the first dose, such
as inability to aspirate CSF at the end of the injection, injec-
tion of less than the intended dose due to unexpected
patient movement or inadvertent disconnection of the
needle from the syringe during injection, and more than
three attempts to enter the subarachnoid space.
After the injection of LA, the extent of the sensory block
was assessed by cold-warm discrimination with an ether
swab. If the patient fulfilled the entry criteria, oral informed
consent for taking a CSF sample was obtained from the
patient. The Regional Ethics Committee waived the need
for written consent because no change in clinical manage-
ment occurred and the volume of the test sample was less
than that of the injected LA. During the second puncture,
immediately before injection of the second dose of LA, a 1
ml sample of lumbar CSF was obtained and set aside. The
sample was frozen immediately and stored at 2208C until
analysis. CSF bupivacaine concentrations were measured
after termination of the study period using high-performance
liquid chromatography as previously described.14 The lower
limit for quantification with this method is 0.05 mg ml21.
Patient position (sitting or lateral) and the lumbar segment
for the first and second punctures were chosen according to
the clinical judgement of the responsible anaesthesiologist.
The needle types used were Sprotte 24 G in patients
younger than 55 yr and Quincke 22 G or 25 G in patients
older than 55 yr according to our departmental clinical prac-
tice at the time of this study. The bupivacaine doses were
15–20 mg for women and 17.5–22.5 mg for men.
Results
During the study period, 2600 spinal anaesthetics were
performed. FSA was observed in 71 patients (2.7%). No
CSF sample was obtained in 45 patients because general
anaesthesia was used as a rescue technique, obvious tech-
nical difficulties during injection, or patient refusal. Four
additional patients were excluded because of adminis-
tration of hyperbaric bupivacaine. In 22 patients, bupiva-
caine concentrations were measured. However, the data
from two of these patients were excluded from analysis
because the circumstances of the first and second taps
were not sufficiently documented. The data of the remain-
ing 20 patients (0.77%) are summarized in Table 1.
All CSF samples were obtained 15–45 min after the
first injection (median: 25 min). The measured CSF con-
centration values were between 3.36 and 1020 mg ml21.
Individual patient data, doses, technical details (needle
type, site of first and second puncture, and patient posi-
tioning), and extent of sensory block before aspiration of
the CSF sample are listed in Table 1. Six patients had a
complete failure, that is, no sensory block at all, including
the sacral dermatomes. The bupivacaine CSF concen-
trations measured in these six patients were between 3.36
and 106.0 mg ml21. The lowest measured concentration in
a patient with partial but inadequate anaesthesia was 11.84
mg ml21. Figure 1 shows the relationship between the
number of blocked segments and the corresponding
lumbar CSF concentrations.
Discussion
We found a wide range of bupivacaine concentrations in
the lumbar CSF of patients with FSA. An important point
for the interpretation of our data is defining a threshold for
lumbar bupivacaine CSF concentrations above which a
sufficient block should be observed. On the basis of the
available data15 and the fact that all our samples were
obtained 15–45 min after the initial lumbar puncture, we
assumed that a lumbar bupivacaine CSF concentration of
73 mg ml21 should lead to an adequate block. This con-
centration represents the 5th percentile of the concen-
trations sampled during the same time-span in 37 patients
with adequate SA by Ruppen and colleagues.15 In our
series of 20 patients with FSA, eight patients had a lumbar
CSF bupivacaine concentration ,73 mg ml21 and 12
patients a concentration .73 mg ml21 (Table 1).
Interestingly, only one of six patients with a completely
FSA had a bupivacaine concentration above this threshold
(106 mg ml21). Resistance to bupivacaine, as suggested in
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two reports,16 17 cannot explain the completely FSA in
these six patients because they all developed adequate
anaesthesia after the repeated injection. A more likely
cause for completely or partially FSA is the failure to
inject a sufficient dose of LA into the CSF as a result of
unrecognized technical problems. Alternatively, an unanti-
cipated large lumbar CSF volume could also explain
inadequately low bupivacaine concentrations.18 19 A large
variability (43–81 ml) of lumbosacral CSF volumes calcu-
lated from MRI sequences has been suggested as the most
important factor contributing to the variability in spread of
SA.6 However, this interpretation is questioned by the fact
that exclusion of one of the 10 volunteers in that study
would eliminate the statistical significance of the corre-
lation between lumbosacral CSF volume and spread of
SA.20 Inadvertent (partial) subdural or epidural injection
could also explain low CSF bupivacaine concentrations. In
an unfixed anatomic preparation of a human spinal
column, Mollmann and colleagues7 were able to reproduce
injection of LA into the subdural space in all preparations
with a Sprotte needle but not with a Quincke needle. In
our series, only three injections were performed with
Sprotte needles, and only one of these patients had a CSF
concentration below 73 mg ml21. Hence, this was not a
major cause of FSA in our series. Maldistribution of LA
and sampling at the ‘wrong’ anatomical level could be
another explanation for low CSF concentrations of bupiva-
caine. In one of the eight patients with CSF bupivacaine
concentrations ,73 mg ml21, the CSF sample was
obtained one interspace higher, and in two patients one
interspace lower than where the primary injection of LA
had taken place (Table 1).
Maldistribution could be the most important explanation
for the FSA in the 12 patients who had CSF bupivacaine
concentrations .73 mg ml21 (106–1020 mg ml21).
Maldistribution needs to be discussed with an understand-
ing of the factors determining intrathecal drug spread. The
distribution of plain bupivacaine is somewhat unpredict-
able.21 In an extensive review, Hocking and Wildsmith21
discuss characteristics of the injected LA, clinical
Table 1 Characteristics of patients with FSA from whom CSF samples were obtained. BMI, body mass index; FSA, failed spinal anaesthesia; Patient position,
patient position during performance of the initial spinal anaesthetic. Needle: Q, Quincke; S, Sprotte. Conc., bupivacaine concentration in the cerebrospinal fluid
Patient
number
Age
(yr)
Sex Height
(m)
Weight
(kg)
BMI
(kg
m22)
Previous
FSA
Dose
(mg)
Patient
position
Needle First
tap
Level of
sensory
blockade
Delay
to
sample
(min)
Second
tap
Conc.
(mg
ml21)
1 86 F 1.64 56 21 X 17.5 Lateral Q 22 G L4/5 None 40 L5/S1 3.36
2 83 M 1.70 74 26 20.0 Sitting Q 25 G L4/5 Right:
L4, left:
none
20 L5/S1 11.84
3 60 M 1.61 85 33 20.0 Sitting Q 25 G L3/4 Patchy:
right:
S2–L1,
left: L5–
T10
45 L3/4 19.02
4 67 M 1.70 58 20 17.5 Sitting Q 25 G L2/3 None 20 L2/3 20.98
5 53 F 1.60 47 18 20.0 Lateral S 24 G L3/4 None 15 30.17
6 63 F 1.60 60 23 17.5 Sitting Q 25 G L3/4 Patchy
T12
15 L3/4 32.28
7 79 M 20.0 Lateral Q 25 G L4/5 None 20 L2/3 50.42
8 52 F 1.58 55 22 15.0 Lateral Q 25 G L3/4 None 15 L3/4 55.66
9 66 M 82 22.5 Sitting Q 25 G L3/4 None 25 L3/4 106.02
10 63 M 1.92 89 24 20.0 Lateral Q 25 G L3/4 L1 35 L2/3 114.48
11 70 M 1.65 66 24 20.0 Lateral Q 25 G L4/5 L3 40 L3/4 127.95
12 52 M 1.60 56 22 20.0 Lateral Q 25 G L3/4 L5 40 L3/4 137.50
13 78 F 1.51 63 28 17.5 Lateral Q 22 G L3/4 Patchy
T10
30 L2/3 137.71
14 69 M 1.76 80 26 X 17.5 Sitting Q 25 G L3/4 Right:
L3, left:
none
15 L3/4 139.27
15 81 F 1.60 68 27 17.5 Lateral Q 25 G L3/4 T12 35 L4/5 160.16
16 56 M 1.65 65 24 22.5 Sitting Q 25 G L3/4 L3 30 L3/4 192.24
17 82 F 1.68 60 21 15.0 Lateral Q 25 G L3/4 L4 30 L3/4 194.74
18 42 F 1.57 47 19 17.5 Lateral S 24 G L4/5 Patchy
L1
20 L3/4 204.49
19 65 F 17.5 Lateral Q 25 G L4/5 Right:
L3, left:
L4
20 L3/4 253.65
20 22 F 1.75 54 18 17.5 Lateral S 24 G L4/5 Right:
T12, left:
L3
30 L3/4 1020.24
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technique including patient position, the level of injection,
type of needle and direction of the needle opening, fluid
currents in the CSF generated by injection of the LA, and
patient characteristics as factors that may influence
intrathecal distribution of LA. All our patients received
plain bupivacaine that is slightly hyperbaric at room temp-
erature and slightly hypobaric at body temperature.21 As
the LA was always stored at room temperature and all
patients were normothermic, the slightly changing baricity
of bupivacaine cannot explain the heterogeneity of our
results. The injected volumes of bupivacaine ranged from
3 to 4.5 ml in our patients. This large range should also
not have had a major impact on intrathecal drug spread as
an increase of 50% in volume has been shown to increase
the mean spread only by one dermatome.21 The clinical
technique used is a more important factor influencing dis-
tribution of bupivacaine, particularly the level of injection.
With plain solutions, a higher level of injection leads to
greater cephalad spread even if the difference in injection
level is only one interspace.21 Results of studies investi-
gating the speed of injection of LA into the subarachnoid
space are conflicting, but faster injections of plain bupiva-
caine probably lead to greater spread.21 As we did not
control for speed of injection, this factor may have con-
tributed to the variability of bupivacaine in the CSF.
Weight, height, and vertical length of the vertebral column
of patients correlate with the distribution of LA after sub-
arachnoid injection of plain bupivacaine. However, the
predictive value of these variables is low.21 Patient posi-
tioning during injection of bupivacaine was not standar-
dized in our study but should not have an influence on the
subarachnoid distribution of plain bupivacaine 0.5%.21
Effects of needle type and direction of needle opening
have, to our knowledge, not been investigated with plain
bupivacaine. Although these factors may explain some of
the heterogeneity of our data, they are unlikely to fully
explain FSA. In contrast, individual anatomical factors
including the configuration of the spinal column (kyphosis,
lumbar lordotic curvature) may influence distribution of
the LA or even cause maldistribution.21 If SA with plain
bupivacaine is repeated on a second occasion, using
exactly the same technique, a block with an extent similar
to the first SA results.22 23 Two of our patients had a
history of FSA. Other anatomical factors that may limit
the distribution of the injected LA are fibrous attachments
and membranous structures in the subarachnoid space.
Fibrous attachments were found between nerve roots,
between nerve roots and the arachnoid membrane at one
or more spinal levels in 16 of 26 autopsy subjects studied
using endoscopy, or both. In another three subjects, a
membranous structure was identified in the posterior
midline of the subarachnoid space.24 By limiting the distri-
bution of the injected LA, these fibrous attachments and
membranes may be associated with a variation in the
extent of SA.
The single patient with a very high (1020 mg ml21)
bupivacaine CSF concentration warrants special attention.
This concentration is higher than the concentrations
reported by Ruppen and colleagues15 and led to an incom-
plete block (L3 left, T12 right). Injection into a low
lumbar CSF volume could be assumed: 17.5 ml would be
appropriate to achieve this concentration with the used
dose of 17.5 mg. However, such a CSF volume is far
below the values that were found in an MRI study.6
Moreover, such a small CSF volume alone would not
explain the FSA. Some other factor, probably anatomical,
leading to maldistribution must have been present.
Injection into a (congenital) spinal arachnoid25 or s.c.
cyst26 has been proposed but seems unlikely in view of the
normal neurological presentation of the patient.
Our findings might support concerns about neurotoxi-
city after repeated injections of bupivacaine into the sub-
arachnoid space. Although our data do not allow drawing
any conclusion on this issue, a correlation between bupi-
vacaine dose and neurotoxicity has been demonstrated in
dogs.11 Considering that more than half of the measured
CSF concentrations in our patients were in a range that
should have led to an adequate block, we agree with
Drasner and Rigler13 that if a second dose is to be con-
sidered, careful testing including the sacral dermatomes
should precede the injection. We suggest that if any
sensory anaesthesia is present, the second injection
should not be performed as maldistribution may be
present. On the other hand, some of the doses we used
were rather large and it may be inappropriate to extrap-
olate our suggestion to patients who receive lower doses
of bupivacaine. An alternative approach would be to use
repeat injections, provided the total amount administered
Bupivacaine CSF concentration ( g ml–1)
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Fig 1 Bupivacaine concentrations in the lumbar CSF and the number of
blocked segments. Bilateral segments are counted separately and were
counted as follows: starting from S5, each blocked segment was added to
the number of blocked segments, for example, a patient with a block
level of L5 on the right side and a level of L3 on the left side would be
represented by 14 blocked segments (right: S5, S4, S3, S2, S1, L5 and
left: S5, S4, S3, S2, S1, L5, L4, L3, i.e. 6þ8 segments). Dotted line: 73
mg ml21.
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does not exceed a dose that the clinician would consider
reasonable as a single injection.
Two limitations of our protocol need consideration: in
order to avoid unnecessary lumbar punctures for study
purposes only, sampling of CSF did not always take place
at the same interspace as the primary injection of LA had
taken place. On the basis of experimental data from an
upright spinal canal model, LA concentrations should not
be markedly influenced by choosing a modestly distant
interspace.27 However, models of the spinal canal lack a
representation of the spinal cord and the cauda equina,
which may act as baffles to the generation of fluid cur-
rents.21 We cannot exclude that some of our measurements
represent local values. On the other hand, inadequately
high local concentrations of LA in the subarachnoid space
are not influenced by the interspace at which the sample
was obtained. The second problem is the variable time-lag
between the injection of bupivacaine and sampling for
determination of the CSF concentration, as bupivacaine
concentrations change during this time.
In summary, we report CSF concentrations of plain
bupivacaine in 20 patients with FSA. Patients in whom
obvious technical problems or insufficient dosage of LA
could explain FSA were excluded. We found a wide
range of CSF concentrations with more than half of the
values in a range where adequate block should have been
present. Inadequately low CSF concentration of bupiva-
caine due to failure to realize technical problems during
injection of the LA is the most likely explanation for
FSA when low concentrations are present. Maldistribution
due to anatomical factors is probably the most frequent
cause of FSA in cases with adequate CSF concentrations,
but further studies are needed to clarify the cause of FSA
in such patients. Although our data provide no evidence
for a relationship between repeated subarachnoid injec-
tions of LA and neurotoxicity, we suggest that a second
injection of LA after FSA should only be performed in
patients with complete failure or if a repeat injection is
performed in a patient with incomplete failure, the total
amount of LA administered should not exceed a dose that
the clinician would consider reasonable as a single
injection.
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